

annual report ²⁰²⁴

Content.

- 01/ EXECUTIVE SUMMARY & GOVERNANCE
- 02/ FINANCIALS
- 03/ SHAPING PUBLIC POLICY
- 04/ EQUALITY, DIVERSITY, INCLUSION (EDI), & SUSTAINABILITY
- 05/ ESGO CONGRESS IN BARCELONA

- 06/ ESGO SCIENTIFIC
- 07/ IJGC JOURNAL
- 08/ GUIDELINES & QUALITY INDICATORS
- 09/ CENTRE ACCREDITATIONS
- 10/ TRAINING & EDUCATION
- 11/ PREVENTION
- 12/ ENYGO

- 13/ ENGOT
- 14/ ENGAGE
- 15/ WORLD GYNECOLOGIC ONCOLOGY DAY
- 16/ OVARIAN CANCER COMMITMENT
- 17/ SUPPORTERS

01/

Executive Summary & Governance

2024 marked a year of dynamic growth, strategic progress, and an unwavering commitment to women's health across Europe and beyond. From shaping policy at the European Parliament to launching a landmark ovarian cancer database, ESGO delivered on its mission to raise standards of care, empower future leaders, and expand access to high-quality gynaecological oncology.

ESGO YEAR 2024 IN NUMBERS

- 3430 members in 128 countries
- One annual congress in Barcelona (53 scientific sessions, 105 speakers, 3.5 hours of live surgery, 1218 submitted abstracts and 2,900+ delegates from 100+ countries)
- 33 new ESGO accredited centres
- 12,000+ ovarian cancer patient records captured in the ESGO Database
- 18 certified ESGO fellows, and 115 currently in training
- 50 webinars and 1 virtual conference on cervical cancer elimination in Africa
- 12 issues of the International Journal of Gynecological Cancer published (impact factor 4.5, CiteScore 6.6)
- 126 World Gynaecological Oncology Day events across 45 countries
- 4 sustainability initiatives launched
- 18 Short Clinical Visits

KEY ACHIEVEMENTS

- ESGO headquarters relocated to Brussels
- Governance restructuring and improvement in transparency policy
- Paving the way to become a strategic partner in shaping EU women's health policy
- TransLink initiative kickstarted pan-European translational research collaborations
- Launch of ENYGO-ESGO Mentorship Programme to close the gender leadership gap
- First ESGO guidelines stratified for limited resource settings globally
- Structure of ESGO Exam questions completely revamped into Single Best Answers (SBA) recognised by ESGO
- MoUs signed with 3 sister societies (ASGO, SERGs and EBCOG)

GOVERNANCE

In 2024, ESGO took bold steps to strengthen its foundations for growth, resilience, and greater impact across Europe. From upscaling internal policies and nurturing our in-house staff to relocating its headquarters to Brussels, these changes reflect ESGO's commitment to transparency, collaboration, and leadership in shaping the future of gynaecological oncology.

KEY ACHIEVE —MENTS IN 2024

STANDARD OPERATING PROCEDURES REVISION

- In 2024, ESGO began the overall revision of its policies and Standard Operating Procedures (SOPs) in compliance with the new Articles of Association, with the goal of finalising the process by the end of 2025. Efforts were focused on providing clear SOPs for all activities and ensuring their accessibility to all relevant parties, including ESGO staff, members, and collaborators.

CONFLICTS OF INTEREST POLICY

- To promote transparency and accountability in all decision-making processes, ESGO introduced a Conflict of Interest (COI) policy in 2024. The policy requires all Council members, Officers, Committee Chairs, Working Group members, and ESGO Office Managers and Directors to fill out a COI form. Submitted COIs are actively reviewed, and potential red flags are identified and addressed to ensure impartiality and safeguard the integrity of decisions.
- The COI forms for ESGO Council members are accessible on the ESGO website, and are presented at the annual general assembly.

MOVE TO BRUSSELS

- In a milestone moment for ESGO, the Society successfully relocated its legal and operational headquarters from Switzerland

to Brussels in 2024. This move streamlines ESGO's governance under Belgian law, and positions the Society at the centre of European health policy and advocacy efforts.

- Following approval of revised Articles of Association at the Annual General Meeting in Barcelona, ESGO completed its official registration in Belgium in September 2024. The transition was supported by Ernst & Young Law and included a comprehensive audit process to ensure full regulatory compliance with the Swiss and Belgian laws.
- Today, ESGO operates from two offices, Brussels and Prague. ESGO's new seat is now at Avenue Emmanuel Mounier 83/11, Brussels (the headquarters of EORTC).

STAFF & ORGANISATIONAL GROWTH

- In 2024, ESGO experienced significant staff growth, reaching a total of 18 team members across ESGO, ENGAGe, ENYGO, and ENGOT, with office locations in Prague and Brussels. This increase in staff has been pivotal in supporting the Committees and the successful launch of several new initiatives.

02/ Finances


2024 was a challenging year financially, since ESGO operated out of Switzerland for the first eight months of the year before being officially relocated to Belgium in September.

The transition from Geneva to Brussels demanded significant effort to ensure continuity in financial operations during a time of change.


The 2024 accounts of ESGO Switzerland and ESGO Belgium were reconciled and merged to produce a unified financial statement, which was presented and approved by the ESGO Extraordinary General Assembly on April 11, 2025.

The overviews of income and expenses below reflect activities conducted during the full fiscal year, covering January 1, 2024 to December 31, 2024.

INCOME



EXPENSES



03/

Shaping Public Policy

**In 2024, ESGO
launched a
new advocacy
initiative aimed at
strengthening its
voice in European
health policy...**

**... and championing the needs of women
affected by gynaecological cancers.
Recognising that political engagement
is essential to improving care standards,
access to treatment, and research
funding, ESGO has committed to ensuring
gynaecological oncology features
prominently on the EU health agenda.**

KEY ACHIEVE —MENTS IN 2024

A strategic planning meeting in June brought together ESGO Council members and Committee Chairs to define ESGO's policy direction. This resulted in the development of an advocacy paper outlining the Society's core messages and areas of policy focus.

Following this, ESGO's Executive Committee and Incisive Health consultants met with several influential Members of the European Parliament, including Vytenis Andriukaitis, Tilly Metz, Manuela Ripa, Romana Jerković, Alessandra Moretti, and Stine Bosse.

Key topics addressed in these discussions included:

- ESGO's role in hospital accreditation and clinical training to ensure consistent standards of care across Europe.
- The need to increase the availability of clinical trials in gynaecological oncology to expand access to innovative treatments.
- Leveraging the ESGO clinical database to support EU policy makers with real life certified data.

These efforts led to ESGO being recognised as a strategic partner in the EU's women's health policy landscape – a significant milestone for the Society.

04/

Equality, Diversity, Inclusion & Sustainability

The Equality, Diversity, Inclusion, (EDI) and Sustainability Committee was formally established in 2024 to promote equity and inclusion among healthcare professionals and patients in gynaecological oncology, as well as to advance sustainability across the field.

Chair: Maja Pakiz, Slovenia

KEY ACHIEVE —MENTS IN 2024

GENDER EQUALITY

- ENYGO–ESGO Mentorship Programme was launched in 2024, to support early-career gynaecological oncologists through mentorship focused on leadership, career advancement, and professional growth. A total of 33 mentors and 58 mentees were matched based on expertise and geographical alignment. Their first in-person meeting took place at the ESGO Congress in Barcelona.
- Webinar Series “Equal Chances” was introduced in 2024, tackling key challenges such as gender bias, workplace harassment, work-life balance, and leadership development.

ENVIRONMENT & SUSTAINABILITY

- Formed in 2024, this working group was created in response to the growing environmental footprint of healthcare systems in gynaecological oncology. The group’s mission is to explore strategies for reducing the specialty’s carbon footprint without compromising patient care.
- Its first initiative was to assemble a multidisciplinary team of experts in sustainability, oncology, and research. The group’s inaugural project – a comprehensive survey – aimed to assess awareness and attitudes among healthcare providers toward environmental sustainability in clinical practice.

05/

ESGO Congress in Barcelona

The 25th European Congress on Gynaecological Oncology (ESGO 2024) was successfully held from March 7–10, 2024, in Barcelona, Spain. 2024 marked a pivotal shift, as the ESGO Congress moved to an early-year schedule. The congress attracted over 2,970 participants from more than 100 countries, reinforcing its reputation as a premier event in the field of gynaecological oncology.

Barcelona's rich culture and vibrant atmosphere offered an ideal setting for the event, combining modernity with Mediterranean charm. A special acknowledgment goes to Prof. Jordi Ponce, the Congress President, who played an instrumental role in shaping the success of the event. His dedication, hard work, and hospitality were deeply appreciated, ensuring the congress was a memorable and impactful experience for all involved.

**Scientific Programme and Congress Committee Chair:
Prof. Domenica Lorusso, Italy**

KEY ACHIEVE —MENTS IN 2024

SCIENTIFIC PROGRAMME HIGHLIGHTS

- **First Public Presentations:**
The 2024 Congress featured the first public release of 4 major international guidelines and consensus statements. ESGO–ESHRE–ESGE Guidelines on Fertility sparing management in Cervical and ovarian cancers, ESGO–EOTTD–ISSTD–GCIG Gestational trophoblastic disease guidelines, ESGO–EURACAN–GCIG Uterine sarcomas guidelines, and ESGO–ISUOG Consensus statements on ultrasound–guided core–cut biopsy.
- **Live Surgery Session:**
This session, first introduced in 2023, was once again a major highlight. Delegates had the opportunity to witness complex surgical procedures in real–time, allowing for detailed discussions on clinical decision–making and surgical techniques.
- **Multidisciplinary Sessions:**
Engaging debates and roundtables allowed for cross–specialty collaboration, fostering a comprehensive understanding of the evolving landscape of gynaecological oncology.
- **Free communication sessions:**
ESGO 2024 received an impressive **1,218 abstract** submissions: **364** for oral presentations, **185** for **Young Investigator** presentations, **24 late–breaking abstracts**, **69 videos**, **261 posters**, **308 e–posters**, and **7 encore** presentations. A total of **70 oral presentations**, **53 videos**, **194 paper posters**, and **816 e–posters** were presented onsite.

KEY ACHIEVE —MENTS IN 2024

CONGRESS HIGHLIGHTS

- **Helga Salvesen Award:**
Prof. Xavier Mathias-Guiu (Spain) received the award for his exceptional contributions to gynaecological oncology.
- **Young Investigator Session:**
This session highlighted emerging talent in the field, with the best presenter receiving a diploma for their outstanding research.
- **ESGO Run & Walk:**
ESGO 2024 hosted a race for a fifth time. This event unites patients, healthcare professionals, and advocates to raise visibility and break the silence around gynaecological diseases.

SUSTAINABILITY INITIATIVES

In line with ESGO's commitment to environmental sustainability, the 2024 Congress implemented several initiatives to reduce its environmental footprint. A carbon offset fee was contributed to a climate protection project in Rwanda, while proceeds from the ESGO Run/Walk registration were directed towards supporting a cervical cancer screening and prevention project in Ghana.

To minimise waste, most congress materials were provided in digital format, and delegates received reusable water bottles to encourage refilling throughout the event - significantly reducing single use plastic consumption.

ESGO 2024

by numbers



104
countries

105
invited speakers



2970
delegates



1218
abstracts

53
educational sessions



6 Debates



Ask the expert sessions

3,5 hours of live surgery



6
Workshops



7 Happening at ESGO booth



Patient Advocacy Seminar

ESGO Helga Salvesen Translational and Clinical Research Award



230
recordings



ESGO Awareness Run & Walk

06/

Science

The ESGO Scientific Committee is dedicated to fulfilling the ESGO mission of advancing research in gynaecological oncology, promoting scientific collaboration, and facilitating the dissemination of knowledge.

**Chair: Viola Heinzelmann-Schwarz,
Switzerland**

KEY ACHIEVE —MENTS IN 2024

TRANSLINK

- To address fragmented research efforts, ESGO launched TransLink – a structured network aimed at enhancing collaboration and data exchange in translational research. In 2024, ESGO conducted a comprehensive survey to assess interest, capacity, and infrastructure among research centres. Findings will form the development of a centralised repository to support joint research projects and resource sharing.

AWARDS & SURVEYS

- In 2024, ESGO finalised a transparent process for the Lifetime Achievement Award and initiated development

of the Helga Salvesen Translational Research Award. The group also refined ESGO's survey framework to harmonise data collection and ensure scientific integrity. Five surveys were coordinated across the network, contributing to ESGO's evidence-based initiatives.

CENTRAL GRANTS OFFICE (CGO)

- Established in 2024, the CGO strengthens ESGO's capacity to secure external research and education funding, and to support initiatives such as TransLink and the ESGO Database. The CGO's operational structure and grant management processes were also defined.

KEY ACHIEVE —MENTS IN 2024

ESGO DATABASE

- The ESGO Database, led by Nicole Concin and Ane Gerda Eriksson, is a critical initiative designed to centralise data collection across key areas of gynaecological oncology.
- In 2024, over 12,000 patient records from 85 ESGO accredited centres (the founding members of the consortium) were successfully integrated into the ESGO ovarian cancer Database, with a strong focus on ensuring data quality and accuracy. Comprehensive follow-up processes were conducted to guarantee completeness and reliability of the data. Data analyses for four key manuscripts were planned in 2024, focusing on different areas of research.

- To further capitalise on collected data, the ESGO Database Scientific Evaluation Committee (SEC) invited research proposals from ESGO Consortium members, resulting in 52 submissions.
- Swiss Pilot Project Expansion (Assessment of Quality of Care in Gynaecological Oncology during a national centralisation process – Highly Specialised Medicine) In 2024, the Swiss Pilot Project continued to grow, marking a national scale implementation of the ESGO Ovarian Cancer Database. With 14 contracts signed and the first patient record entered, the project is becoming a model for future collaborations with national bodies and ultimately a strong advocacy tool.

07/

IJGC Journal

The International Journal of Gynecological Cancer (IJGC), the official scientific journal of ESGO and the International Gynecologic Cancer Society (IGCS), continues to be a leading source of information and education for a broad readership of clinicians and scientists working in the field of gynaecological oncology.

KEY ACHIEVE- MENTS IN 2024

- In 2024, IJGC published 12 issues, consistent with previous years. The Editor-in-Chief, Dr Pedro Ramirez, released 50 podcasts discussing the latest research from the Journal, of which the top episode amassed over 5000 downloads.
- The top 3 countries with accepted submissions to the Journal were the United States, Italy and Spain. The average time from submission to acceptance was 26 days, and from acceptance to publication was 32 days.
- As for social media, the IJGC gained 629 new followers on X (formerly Twitter), 1092 on Facebook and an impressive 3000 on LinkedIn during its first year on the platform.
- As of 2024, the Journal has an Impact Factor of 4.5 and a CiteScore of 6.6, demonstrating that it is regarded as a high-impact, reputable scientific journal.

08/

Guidelines & Quality Indicators

The ESGO Guidelines Committee is committed to developing, disseminating, and regularly updating evidence-based guidelines for the management of gynaecological cancers. These guidelines are created in close collaboration with related societies whenever possible, ensuring a multidisciplinary and internationally harmonised approach to improving care for women with gynaecological cancers.

Chair: Ane Gerda Zahl Eriksson, Norway

ESGO continues to enhance the integration of these resources into clinical practice through user friendly digital platforms, such as the ESGO Algorithms App.

KEY ACHIEVE —MENTS IN 2024

- Collaborating with 16 partner societies and a wide network of international experts, ESGO increased its output significantly – from 7 publications in 2020 to 24 in 2024. The impact of these guidelines continues to grow. Seven ESGO articles have received between 105 and 914 citations, highlighting their academic relevance, while 21 publications collectively surpassed 176,000 downloads – showcasing their practical value among clinicians worldwide.
- In 2024, the SOPs for guideline updates were reviewed. To ensure ongoing accuracy and relevance, major tumour-type guidelines are reviewed every 2–3 years, with full updates every 4–5 years or sooner when significant new evidence emerges. Complementing the full-length guidelines, pocket versions for all major tumour types are regularly revised and made available on the ESGO website, offering clinicians quick, accessible tools for everyday practice. All new guidelines will include patient representatives to contribute directly to the process, helping to shape guidance that is both clinically sound and sensitive to patient needs.

KEY 2024 ESGO GUIDELINES PUBLICATIONS

- **CONSENSUS STATEMENT ON SURGICAL STEPS IN MINIMALLY INVASIVE SURGERY IN GYNECOLOGIC ONCOLOGY:** transperitoneal and extraperitoneal approach for paraaortic lymphadenectomy

→ [INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER](#)

- **ESGO JOINT QUALITY INDICATORS FOR THE SURGICAL AND RADIOTHERAPEUTICAL MANAGEMENT OF CERVICAL CANCER**

→ [INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER](#)

- **ESGO-ESHRE-ESGE FERTILITY-SPARING TREATMENT AND FOLLOW-UP IN PATIENTS WITH CERVICAL CANCER, OVARIAN CANCER AND BORDERLINE OVARIAN TUMOURS**

→ [LANCET ONCOLOGY](#)

- **ESGO-EURACAN-GCIG GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH UTERINE SARCOMAS**

→ [INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER](#)

MANY OTHER PROJECTS HAVE BEEN INITIATED IN 2024 AND WILL BE PRESENTED AT ESGO CONGRESS IN 2025.

- **ESGO ALGORITHMS APP**

The ESGO Algorithms App continues to evolve, offering clinicians accessible and up-to-date tools for managing gynaecological cancers.

- **KEY ESGO MOBILE APP UPDATES IN 2024**

Cervical Cancer update was launched at ESGO 2024.

New rare tumour algorithms for Cervical Adenocarcinoma, developed in collaboration with GCIG.

09/

Centre Accreditations

The ESGO Centre Accreditation programme is designed to establish and uphold multidisciplinary standards for the care of women with gynaecological cancers. This programme positions ESGO as the leading authority in Europe for setting high standards in clinical care and training within the field of gynaecological oncology.

Chair: Ignacio Zapardiel, Spain

Co-Chairs for training centres: Prof. René H. M. Verheijen, The Netherlands & Prof. Basel Refky, Egypt

Since its launch in 2010, ESGO has developed four key accreditation programmes targeting advanced ovarian cancer, endometrial cancer, cervical cancer and training. These programmes are founded on rigorous scientific research and quality indicators are created by leading specialists in gynaecological oncology.

KEY ACHIEVE- MENTS IN 2024

- **HOSPITAL TRAINING ACCREDITATION:**

18 centres accredited (6 new, 12 re-accredited).

- **ADVANCED OVARIAN CANCER SURGERY:**

5 centres accredited (4 regular - new, 1 Centre of Excellence - re-accredited).

- **ENDOMETRIAL CANCER SURGERY:**

10 centres accredited (9 regular - new, 1 Centre of Excellence - new).

- **ACCREDITED CENTRES BY 2024 IN TOTAL**

125 centres across 40 countries, including 5 non-EU countries (Lebanon, South Korea, India, USA, Egypt).

- **ESGO CANDIDACY PROGRAMME**

The ESGO Candidacy Programme aims to raise standards of gynaecological oncology care by focusing particularly on countries that have not yet

achieved ESGO accreditation. The programme supports centres in resource-limited settings to meet the criteria set for accreditation, which involves analysing local settings, identifying barriers, and providing support to overcome them. Ultimately, the goal is to enhance local clinical care and patient outcomes.

- **KEY ACHIEVEMENTS IN 2024**

Three centres submitted applications from Azerbaijan, Kazakhstan, and Portugal.

New contacts were established with National Ambassadors in Azerbaijan, Bulgaria, Kazakhstan, and North Macedonia.

MAP OF CENTRES ACCREDITED IN 2024



10/

Training & Education

ESGO is committed to advancing the field of gynaecological oncology across Europe by providing high-quality educational opportunities for healthcare professionals. ESGO's mission is to ensure that specialists receive training to the highest standards, equipping them with the skills necessary to deliver optimal care to patients with gynaecological cancers.

**Chair: Daniela Fischerová,
The Czech Republic**

KEY ACHIEVE- MENTS IN 2024

CURRICULUM REVIEW & EXPANSION

- In 2024, ESGO updated its core curriculum for surgical training in gynaecological oncology to reflect the latest scientific advancements and treatment protocols. New specialised modules focused on Diagnostic and Interventional Ultrasound in Gynaecological Oncology and on Women's Health were announced. These modules enable trainees to acquire skills tailored to modern diagnostic and treatment techniques.

ESGO FELLOWSHIP AND CERTIFICATION PROGRAMMES

- **FESGO-EBCOG Diploma:** A collaboration with the European Board and College of Obstetrics and Gynaecology (EBCOG) has resulted in the introduction of the FESGO-EBCOG Diploma. This diploma recognises professionals who complete the ESGO Curriculum, meaning there is now international recognition of ESGO certification.
- In 2024, 18 Fellows completed the training, bringing the total number of certified fellows to 112. Currently, 115 Fellows are registered in the programme and undergoing training at ESGO-certified centres across various locations.

ESGO EXAM

The ESGO Exam structure underwent a major revision in 2024, transitioning from Multiple-Choice Questions (MCQs) to a more rigorous Single Best Answer (SBA) format. This update enhances the assessment of clinicians' critical thinking and clinical decision-making.

- 430 new SBA questions covering 20 essential gynaecological oncology topics.
- Launch of an exam preparatory webinar equipping candidates with tools to excel.
- Memorandum of Understanding (MoU) with EBCOG to align the ESGO Exam with European certification standards.

KEY ACHIEVE —MENTS IN 2024

WEBINARS

- **4 Meet the Surgeon Webinar Series** to bridge theoretical knowledge and surgical practice, featuring expert-led sessions on advanced surgical techniques.
- **13 IJGC Virtual Journal Club** sessions in collaboration with IJGC and IGCS, to provide a global platform for discussing groundbreaking research.

- **4 Partner Societies Webinars** with ASGO and SFCO partner societies focusing on ovarian cancer, endometrial cancer, and fertility preservation.
- **2 Webinars for Non-European Audiences** to address the unique needs of regions like Asia, Latin America, and the Middle East.
- **OncoAlert Colloquium** – a key global event for advancing cancer care and research, with presentations on EC FIGO Staging System and Systemic Therapy for Uterine LMS.
- **8 ESGO Travelling Fellowships** for 1 to 2 months at ESGO accredited centres worldwide.

GESEA LEVEL 3 TRAINING PROGRAMME

In 2024 the GESEA Level 3 oncology pathway developed by ESGE and ESGO was completed, with the aim of offering a European certification in MIS in oncology recognised by the major European scientific societies.

ESGO ENDORSEMENT PROGRAMME

In 2024, ESGO endorsed 28 educational meetings across 17 countries, contributing to national conferences, workshops, and specialised courses.

KEY ACHIEVE —MENTS IN 2024

ESGO eACADEMY

The **ESGO eAcademy** continued to serve as a key resource for gynaecological oncology professionals, and experienced an 11% increase in unique users, reaching 4,074 users and 30,585 visits in 2024.

KEY ADDITIONS IN 2024

- 288 Congress Recordings from the ESGO 2024 Congress.
- New Ultrasound and Surgical Mentorship Series.
- Equal Chances Webinars promoting diversity in gynaecological oncology.
- All webinar recordings (incl. ENYGO Mentorship surgical and Tumor Board webinars) made available on eAcademy.
- The ESGO Textbook of Gynaecological Oncology – Platinum Edition – each chapter features QR codes linking to online resources hosted on eAcademy.

COURSES

- **Advanced Course on Surgical Management of Cervical Cancer:** Held as both an online theoretical pre-course and hands-on training on cadavers in Madrid.
- **Advanced Robotic Gynaecological Oncology Surgery Course:** A hands-on training on cadavers and live tissue in IRCAD, Strasbourg, France.

Prevention

The ESGO Prevention Committee, established in 2019, plays a key role in advancing ESGO's mission to contribute to the global fight against gynaecological cancers. The committee comprises over 50 multidisciplinary experts, including leading doctors from both Europe and low- and middle-income countries, epidemiologists, former WHO leaders, and patient advocates. The committee is proud of its collaborative approach and strong partnership with ENGAGe, the European Network of Gynaecological Cancer Patient Advocacy Groups.

Chair: Murat Gultekin, Turkey

KEY ACHIEVE —MENTS IN 2024

EDUCATIONAL WEBINARS

In 2024, the ESGO Prevention Committee hosted a series of educational webinars, allowing it to raise awareness and share prevention strategies across the field. The webinars included topics on Ovarian Cancer Prevention, HPV Prevention in Pregnancy, Endometrial Cancer Prevention and Vulvar and Vaginal Cancer Epidemiology and Screening. On average, at each webinar, participation amounted to 250 attendees and 100 downloads from the ESGO eAcademy.

ONLINE CONFERENCE: 'HOW TO ELIMINATE CERVICAL CANCER IN AFRICA'

In 2024, the committee organised a pivotal online conference focused on strategies for eliminating cervical cancer in Africa, attracting 668 participants, including general gynaecologists, general practitioners, and gynaecological oncology specialists.

SCIENTIFIC PUBLICATIONS IN 2024

- **GENITAL TRACT MICROBIOTA COMPOSITION PROFILES AND USE OF PREBIOTICS AND PROBIOTICS IN GYNAECOLOGICAL CANCER PREVENTION:** Review of Current Evidence

→ [LANCET MICROBE](#)

- **VALIDATED HPV TESTS USABLE IN CERVICAL CANCER SCREENING ON CLINICIAN-COLLECTED CERVICAL SPECIMENS**

→ [HPV WORLD](#)

- **CRITERIA FOR SECOND-GENERATION COMPARATOR TESTS IN VALIDATION OF NOVEL HPV DNA TESTS FOR USE IN CERVICAL CANCER SCREENING**

→ [WILEY JOURNAL OF MEDICAL VIROLOGY](#)

- **ADVANCING CERVICAL CANCER PREVENTION IN AFRICA:** ESGO's Strategic Initiatives and Collaborative Efforts

→ [IJGC CORNERS OF THE WORLD](#)

- **PROPHYLACTIC HPV VACCINATION IN HPV-RELATED GYNECOLOGIC CANCERS:** European Society of Gynaecological Oncology (ESGO) prevention committee opinion

→ [INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS](#)

12/

ENYGO

The European Network of Young Gynaecological Oncologists (ENYGO) provides a dynamic platform for young oncologists to connect, share knowledge, and grow within a supportive, international network. As part of ESGO's broader commitment to excellence in education and clinical practice, ENYGO ensures that early-career professionals have access to the tools, mentorship, and opportunities needed to thrive.

President: Aleksandra Strojna, Germany

KEY ACHIEVE —MENTS IN 2024

EDUCATIONAL ACTIVITIES

- **3 Surgical Mentorship Webinar Series** – a new activity launched in 2024, this series was designed to support the development of surgical skills in gynaecological oncology. It features live webinars where trainees present unedited surgical videos for real-time expert feedback, fostering a highly interactive learning environment.
- **3 ESGO–ENYGO Tumour Board Webinar Series**, featuring real clinical cases on Endometrial Cancer, Cervical Cancer, and Cervical Cancer in Pregnancy. The series provides interactive live educational sessions on gynaecological cancer treatment strategies. Three webinars took place in 2024.
- **3 ENYGO Short Clinical Visits** for 18 participants in reference centres across Europe – including Charité University Hospital (Berlin, Germany), Faculty Hospital Kralovske Vinohrady (Prague, the Czech Republic), and Vall d’Hebron University Hospital (Barcelona, Spain).
- **The ENYGO Introduction to Robotic Surgery Course** provided early career young surgeons with training on Da Vinci robotic surgery techniques at IRCAD, France.

SCIENTIFIC PRODUCTIONS

- **ENYGO-IJGC FELLOWS INTERVIEWS SERIES** published on the ENYGO Youtube channel
- **BEST OF ESGO 2024** – best original research presented at the 25th European Congress on Gynaecological Oncology
- [INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER](#)

- **HIGHLIGHTS FROM THE 25TH EUROPEAN CONGRESS ON GYNAECOLOGICAL ONCOLOGY IN BARCELONA**
- [INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER](#)
- **HIGHLIGHTS FROM THE 24TH EUROPEAN CONGRESS ON GYNAECOLOGICAL ONCOLOGY IN ISTANBUL**
- [INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER](#)
- **LIFE REPORT** (Literature for ENYGO) – a comprehensive literature review, led by young professionals, synthesising the latest research and clinical guidelines in gynaecological oncology and ensuring that members stay informed on the most relevant topics in the field. The LiFE 18 report involved 7 editors and 37 authors from across Europe, covering 33 key topics.
- [INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER](#)

- **ENYGO SURVEYS**
ENYGO continued to conduct surveys on various aspects of gynaecological oncology, allowing them to capture real-world data on clinical practices, treatment approaches, and emerging trends.
- **GLOBAL PRACTICE PATTERNS OF SENTINEL LYMPH NODE BIOPSY IN ENDOMETRIAL CANCER: A Survey from ENYGO**
- [INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER](#)
- **MANAGEMENT OF PATIENTS WITH HYPERSENSITIVITY TO PLATINUM SALTS AND TAXANE IN GYNECOLOGICAL CANCERS: A Cross-Sectional Study by ENYGO**
- [INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCERS](#)

13/

ENGOT

The European Network of Gynaecological Oncological Trial Groups (ENGOT) is the research arm of ESGO conducting collaborative clinical trials in gynaecological cancers. In 2024, ENGOT held two General Assemblies with representatives from 21 trial groups across 33 European countries.

Co-Chairs: Prof. Isabelle Ray-Coquard, France and Mrs. Elena Biagioli, Italy

KEY ACHIEVE- MENTS IN 2024

STRATEGIC MEETING & PRIORITIES

In February 2024, ENGOT held a strategic meeting in Italy, where key issues in the field were discussed:

- Effective coordination of clinical trials across multiple countries.

- Promotion of academic studies and their integration into clinical practice.
- Acceleration of drug development processes for gynaecological cancers.
- Mentoring of young investigators to ensure continued innovation and leadership in the field.

ENGOT TRIALS & GLOBAL COLLABORATION

In 2024 ENGOT opened 28 trials. These trials cover a variety of cancers, including 15 trials for ovarian cancer, 7 trials for endometrial cancer, 4 trials for cervical cancer, and 2 basket studies. In addition, ENGOT

collaborates globally with international research groups such as GOG-F in the USA, APGOT in the Asia-Pacific region, and LACOG in Latin America, extending its research impact beyond Europe.

GYNAECOLOGICAL CANCER ACADEMY (GCA)

In 2024, the GCA workshop was held in Italy, gathering 42 participants for an intensive one and a half days of training led by 6 mentors. 12 patient representatives joined the meeting for the first time, enriching the dialogue with valuable perspectives.

14/

ENGAGe

ENGAGe (the European Network of Gynaecological Cancer Patient Advocacy Groups) remains dedicated to empowering individuals affected by gynaecological cancers through patient advocacy, education, collaboration, and raising awareness.

Co-Chairs: Kim Hulscher, The Netherlands and Prof. Philippe Morice, France

KEY ACHIEVE- MENTS IN 2024

ENHANCED COMMUNICATION & ENGAGEMENT

ENGAGe strengthened connections with members through one-on-one meetings, a monthly newsletter, and EEG meeting summaries. Four new member organisations joined, expanding its reach across Europe.

STRENGTHENED ESGO PRESENCE

Permanent representation in both the Prevention and Guidelines Committees was secured, ensuring that patient perspectives are integrated into ESGO's strategic initiatives.

EXTERNAL ENGAGEMENT

ENGAGe actively engaged in key congresses, including ESGO Congress, Eurogin, ESMO, IGCS and IPVC, reinforcing its role in the wider gynaecological oncology community.

12TH PATIENT ADVOCACY SEMINAR (PAS)

Held in Barcelona, Spain, with 60 participants from 27 countries, the PAS coincided with International Women's Day and focused on:

- **Cervical Cancer Prevention:** Highlighting HPV vaccination and self-testing.
- **Clinical Trials Workshop:** ENGOT and ENGAGe experts provided in-depth insights into the design of clinical trials and the essential role of patient involvement.
- **Innovations in Gynaecological Cancer:** Updates on endometrial cancer, immunotherapy, and surgical trends.
- **Advocacy and Policy Change:** Training in policy influence and systematic change.

KEY ACHIEVE- MENTS IN 2024

EDUCATIONAL ACTIVITIES

- 5 webinars covered topics from ovarian cancer to physical activity post-treatment, with a 20% increase in attendance.
- 5 new brochures were published, including vulvar cancer materials. The brochure library now holds 30 topics in 26 languages.

QUALITY OF LIFE (QOL) PROJECT

Focused on emotional support and communication. Key tool Diagnosis Delivery Cards, developed by an Irish member (ISGO-PPI), are being translated for broader use.

ENDOMETRIAL CANCER AWARENESS CAMPAIGN

This campaign promoted early detection via:

- Social Media Content featuring ENYGO ambassadors.
- Expert Webinar with 60 attendees.
- Updated Brochure reflecting medical advances and FIGO staging.

CLINICAL TRIALS PROJECT

A workshop during the Patient Advocacy Seminar and participation in the ENGOT Gynaecologic Cancer Academy workshop advanced member knowledge. Eight new members joined the initiative.

ENGAGE TEENS

This initiative focused on youth education via social media, training sessions, and an in-person meeting in Budapest. TEENs supported the World Gynecologic Oncology Day HPV campaign and created content for platforms like Instagram and TikTok.

15/

World Gynecologic Oncology Day

The 6th World Gynecologic Oncology Day took place on September 20, 2024, marking a significant effort to raise global awareness about gynaecological cancers. A central goal of this year's campaign was to address the stigma surrounding gynaecological cancers, which often causes patients to delay seeking medical attention due to shame or lack of awareness. The campaign worked to dismantle these barriers and encourage timely screening and diagnosis.

KEY ACHIEVE —MENTS IN 2024

- **126 local events** organised across 45 countries around 6 continents.
- Over **4.62 million social media impressions**, and 500 shared stories from users across the world.

WEBSITE & MATERIAL ENGAGEMENT

- The new website proved to be an essential resource, attracting 12,600 visitors and facilitating over 1,000 downloads of educational materials.
- Monthly newsletters kept the audience engaged throughout the campaign, with an impressive 50% open rate, ensuring that participants remained informed and involved in ongoing activities.

16/

Ovarian Cancer Commitment (OCC)

The Ovarian Cancer Commitment (OCC) is a strategic initiative established by the European Society of Gynaecological Oncology (ESGO), the European Network of Gynaecological Cancer Advocacy Groups (ENGAGE), and AstraZeneca. Launched in 2022 to enhance the experience and survival of women with ovarian cancer, OCC continues its mission to raise awareness, educate key stakeholders, and advocate for improved ovarian cancer care.

KEY ACHIEVE —MENTS IN 2024

OLIVIA DIGITAL PATIENT PATHWAY EXPANSION

Olivia, OCC's [digital platform](#), offers a user-friendly and comprehensive resource designed to guide ovarian cancer patients and their support networks through every stage of the cancer journey. In 2024, Olivia saw significant expansion:

- **National Launches:** In April 2024, Austrian Olivia was officially introduced at the AGO Congress in Salzburg, Austria, marking a significant milestone in the initiative's expansion across Europe.
- **Global English Pathway:** OCC updated and reviewed the global English language version of Olivia, ensuring that all content is current, relevant, and accessible for patients and their families worldwide.

“DON'T OVERLOOK” ADVOCACY WORKSTREAM

The “Don't Overlook” workstream focused on equipping Patient Advocacy Groups (PAGs) with the knowledge, tools, and strategies needed to accelerate access to specialised ovarian cancer care across Europe. Major developments in 2024 included:

- Advocacy Planning Workshop and Toolkit
- 4 Educational Online Events

17/

Supporters

ESGO extends its sincere thanks to all our supporters. Your ongoing commitment has been instrumental in helping us advance the field of gynaecological oncology. Through your support, we've been able to deliver impactful educational programmes, foster innovation, and strengthen our global community.

Thank you for being a vital part of our mission to improve the care and outcomes for women with gynaecological cancers.

KLS martin
GROUP

pharma &

Roche

CASIO
D'Z IMAGE

Eisai

GSK

OLYMPUS

RAND

B | BRAUN
SHARING EXPERTISE

Corcept
THERAPEUTICS

Daiichi-Sankyo

SUTRO
BIOPHARMA
DIVERSITY | EQUALITY | AUTHENTICITY

REGENERON

Medtronic

CONMED

HOLOGIC

AstraZeneca

KARTOS THERAPEUTICS

MSD

Rovers
medical devices

MENARINI
group

Stemline
A Menarini Group Company

TORL
BIOTHERAPEUTICS

stryker

MEDICA

abbvie

BIONTECH

w. wisepress.com
your medical bookshop

sysmex

INTEGRA

Genmab

ESPINER

INTUITIVE

immur.gen

zentalis

GILEAD

thank you.